Safety assessment of titanium dioxide (E171) as a food additive

Abstract

The present opinion deals with an updated safety assessment of the food additive titanium dioxide (E 171) based on new relevant scientific evidence considered by the Panel to be reliable, including data obtained with TiO₂ nanoparticles (NPs) and data from an extended one-generation reproductive toxicity (EOGRT) study. Less than 50% of constituent particles by number in E 171 have a minimum external dimension < 100 nm. In addition, the Panel noted that constituent particles < 30 nm amounted to less than 1% of particles by number. The Panel therefore considered that studies with TiO₂ NPs < 30 nm were of limited relevance to the safety assessment of E 171. The Panel concluded that although gastrointestinal absorption of TiO₂ particles is low, they may accumulate in the body. Studies on general and organ toxicity did not indicate adverse effects with either E 171 up to a dose of 1,000 mg/kg body weight (bw) per day or with TiO₂ NPs (> 30 nm) up to the highest dose tested of 100 mg/kg bw per day. No effects on reproductive and developmental toxicity were observed up to a dose of 1,000 mg E 171/kg bw per day, the highest dose tested in the EOGRT study. However, observations of potential immunotoxicity and inflammation with E 171 and potential neurotoxicity with TiO₂ NPs, together with the potential induction of aberrant crypt foci with E 171, may indicate adverse effects. With respect to genotoxicity, the Panel concluded that TiO₂ particles have the potential to induce DNA strand breaks and chromosomal damage, but not gene mutations. No clear correlation was observed between the physico-chemical properties of TiO₂ particles and the outcome of either in vitro or in vivo genotoxicity assays. A concern for genotoxicity of TiO₂ particles that may be present in E 171 could therefore not be ruled out. Several modes of action for the genotoxicity may operate in parallel and the relative contributions of different molecular mechanisms elicited by TiO₂ particles are not known. There was uncertainty as to whether a threshold mode of action could be assumed. In addition, a cut-off value for TiO₂ particle size with respect to genotoxicity could not be identified. No appropriately designed study was available to investigate the potential carcinogenic effects of TiO₂ NPs. Based on all the evidence available, a concern for genotoxicity could not be ruled out, and given the many uncertainties, the Panel concluded that E 171 can no longer be considered as safe when used as a food additive.

Keywords: CAS No 13463‐67-7; E 171; Titanium dioxide.

Figure 1

In vitro micronucleus and chromosomal aberrations studies. Summary of test results from 56 studies reported in 44 papers, NANOGENOTOX Project, 2013 (Documentation provided to EFSA No 7 and 8) and Documentation provided to EFSA No 15


1. *: Some of the studies used more than one test material and in these cases, the results are reported separately.

Figure 2

In vivo micronucleus and chromosomal aberration studies – Summary of test results

Figure 3

In vitro Comet assays – Summary of study results from 142 studies reported in 68 publications


1. *: Some of the studies used more than one test material and in these cases, the results are reported separately.

Figure 4

In vivo Comet assays – Summary of test results


1. *: Some of the studies used more than one test material and, in these cases, the results are reported separately.

Figure I.1

Boxplots comparing Ti levels in blood (μg/g blood) for treatment concentration and sex combinations for each generation and cohort (Documentation provided to EFSA No 18) (for further explanation see text above)

Figure I.2

Boxplots comparing Ti levels in urine (μg/g blood) for treatment concentration and sex combinations for each generation and cohort (Documentation provided to EFSA No 18)